---
layout: default
title: Ramucirumab
parent: 僅模型預測 (L5)
nav_order: 312
evidence_level: L5
indication_count: 10
---

# Ramucirumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ramucirumab: From Solid Tumor Oncology to Uterine Ligament Adenocarcinoma

## One-Sentence Summary

Ramucirumab is an anti-VEGFR2 monoclonal antibody used in solid tumor oncology; its specific original indication is not captured in this evidence pack. The TxGNN model predicts it may be effective for **Uterine Ligament Adenocarcinoma**, but this prediction is currently supported by **0 clinical trials** and **0 publications** — it rests entirely on knowledge-graph association strength and a class-level anti-angiogenic mechanism hypothesis.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in evidence pack (original_indications field empty; DrugBank extraction incomplete) |
| Predicted New Indication | Uterine Ligament Adenocarcinoma |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in structured form (original_moa is a data gap). Based on the rationale captured for this candidate, ramucirumab is an anti-VEGFR2 monoclonal antibody that mechanistically inhibits angiogenesis in solid tumors, giving it theoretical broad-spectrum potential against highly vascularized malignancies — including gynecologic cancers.

This is, however, a **class-level extrapolation, not a disease-specific finding**. Uterine ligament adenocarcinoma is a rare histological subtype, and no direct clinical, preclinical, or observational data linking ramucirumab to this indication exists in any of the queried sources (ClinicalTrials.gov, ICTRP, PubMed all returned zero results). The extremely high TxGNN score (99.95%) reflects the strength of the model's learned graph association, not clinical validation — the same pattern repeats across all 10 top-ranked predictions for this drug, which are all rare uterine/cervical adenocarcinoma subtypes clustered together in the knowledge graph, each equally lacking supporting evidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Finland Market Information

Ramucirumab has no marketing authorizations in Finland (market status: not marketed, 0 licenses on file).

---

## Cytotoxicity

Ramucirumab is an antineoplastic agent (anti-VEGFR2 monoclonal antibody used in solid tumor oncology).

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (anti-VEGFR2 monoclonal antibody / anti-angiogenic agent) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate cannot yet advance past the S0 (model-prediction-only) stage. The TFDA/regulatory package insert data gap is classified **Blocking** — it explicitly prevents entry into S1 safety pre-evaluation — and none of the top 10 predicted indications (all rare uterine/cervical adenocarcinoma subtypes, ranked 814–978 by TxGNN) have any supporting clinical trial or literature evidence.

**To proceed, the following is needed:**
- Original indication and approved-label data for ramucirumab (currently missing from evidence pack)
- TFDA/Fimea package insert (warnings, contraindications) — Blocking gap, required before any S1 safety review
- Confirmed mechanism of action detail via DrugBank API (High severity gap)
- At minimum, preclinical or mechanistic studies specific to gynecologic malignancies before this candidate can move beyond model-prediction-only status
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

